Published in Nat Med on August 03, 2003
Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100. Blood (2008) 3.77
Context, tissue plasticity, and cancer: are tumor stem cells also regulated by the microenvironment? Cancer Cell (2005) 3.67
Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood (2008) 3.67
Environment-mediated drug resistance: a major contributor to minimal residual disease. Nat Rev Cancer (2009) 3.49
Instructive role of the vascular niche in promoting tumour growth and tissue repair by angiocrine factors. Nat Rev Cancer (2010) 3.48
CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer progression. Cancer Metastasis Rev (2010) 3.24
Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML. Nat Biotechnol (2010) 3.13
The leukemic stem cell niche: current concepts and therapeutic opportunities. Blood (2009) 2.85
A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia. Blood (2012) 2.77
Leukemia stem cells and microenvironment: biology and therapeutic targeting. J Clin Oncol (2011) 2.52
Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia. Blood (2006) 2.45
Suppression of CXCL12 production by bone marrow osteoblasts is a common and critical pathway for cytokine-induced mobilization. Blood (2009) 2.25
Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase. J Clin Invest (2007) 2.05
Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia. Haematologica (2009) 1.87
Contribution of bone microenvironment to leukemogenesis and leukemia progression. Leukemia (2009) 1.77
Mechanisms and insights into drug resistance in cancer. Front Pharmacol (2013) 1.70
The hematopoietic stem cell niche--home for friend and foe? Cytometry B Clin Cytom (2012) 1.70
Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-β-catenin signaling. Blood (2013) 1.70
The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients. Oncotarget (2010) 1.64
Stem-cell ecology and stem cells in motion. Blood (2008) 1.61
Right on target: eradicating leukemic stem cells. Trends Mol Med (2007) 1.49
Abrogation of PIK3CA or PIK3R1 reduces proliferation, migration, and invasion in glioblastoma multiforme cells. Oncotarget (2011) 1.39
Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment. Oncotarget (2012) 1.34
Therapeutic targeting of microenvironmental interactions in leukemia: mechanisms and approaches. Drug Resist Updat (2009) 1.34
Lack of alpha4 integrin expression in stem cells restricts competitive function and self-renewal activity. Blood (2005) 1.32
Enabling stem cell therapies through synthetic stem cell-niche engineering. J Clin Invest (2010) 1.31
Reciprocal leukemia-stroma VCAM-1/VLA-4-dependent activation of NF-κB mediates chemoresistance. Blood (2014) 1.29
Chemotherapy activates cancer-associated fibroblasts to maintain colorectal cancer-initiating cells by IL-17A. J Exp Med (2013) 1.21
Very late antigen-4 function of myeloblasts correlates with improved overall survival for patients with acute myeloid leukemia. Blood (2008) 1.20
The microtubule-targeting agent CA4P regresses leukemic xenografts by disrupting interaction with vascular cells and mitochondrial-dependent cell death. Blood (2007) 1.17
Role of leukemia cell invadosome in extramedullary infiltration. Blood (2009) 1.16
Of microenvironments and mammary stem cells. Stem Cell Rev (2007) 1.14
Hematopoietic stem cell niche is a potential therapeutic target for bone metastatic tumors. Clin Cancer Res (2011) 1.09
Integrin alpha4 blockade sensitizes drug resistant pre-B acute lymphoblastic leukemia to chemotherapy. Blood (2013) 1.08
The difficulty of targeting cancer stem cell niches. Clin Cancer Res (2010) 1.08
Role of CXCR4 in the pathogenesis of acute myeloid leukemia. Theranostics (2013) 1.05
The increased expression of integrin α6 (ITGA6) enhances drug resistance in EVI1(high) leukemia. PLoS One (2012) 1.01
The mesenchymal tumor microenvironment: a drug-resistant niche. Cell Adh Migr (2012) 0.99
Genetic reduction of class IA PI-3 kinase activity alters fetal hematopoiesis and competitive repopulating ability of hematopoietic stem cells in vivo. Blood (2005) 0.98
Dynamic chemotherapy-induced upregulation of CXCR4 expression: a mechanism of therapeutic resistance in pediatric AML. Mol Cancer Res (2013) 0.98
Bone marrow mesenchymal stem cells from leukemia patients inhibit growth and apoptosis in serum-deprived K562 cells. J Exp Clin Cancer Res (2009) 0.97
Dependence of acute myeloid leukemia on adhesion within the bone marrow microenvironment. ScientificWorldJournal (2012) 0.96
Gene expression profiling reveals differences in microenvironment interaction between patients with chronic lymphocytic leukemia expressing high versus low ZAP70 mRNA. Haematologica (2009) 0.95
High expression of the very late antigen-4 integrin independently predicts reduced risk of relapse and improved outcome in pediatric acute myeloid leukemia: a report from the children's oncology group. J Clin Oncol (2010) 0.95
MLL-rearranged acute lymphoblastic leukaemia stem cell interactions with bone marrow stroma promote survival and therapeutic resistance that can be overcome with CXCR4 antagonism. Br J Haematol (2013) 0.95
CXCR4 chemokine receptor signaling induces apoptosis in acute myeloid leukemia cells via regulation of the Bcl-2 family members Bcl-XL, Noxa, and Bak. J Biol Chem (2013) 0.93
HSP70 inhibition reverses cell adhesion mediated and acquired drug resistance in multiple myeloma. Br J Haematol (2008) 0.92
Ligand bound beta1 integrins inhibit procaspase-8 for mediating cell adhesion-mediated drug and radiation resistance in human leukemia cells. PLoS One (2007) 0.92
GAS6/Mer axis regulates the homing and survival of the E2A/PBX1-positive B-cell precursor acute lymphoblastic leukemia in the bone marrow niche. Exp Hematol (2009) 0.92
Homing of cancer cells to the bone. Cancer Microenviron (2011) 0.92
Low-dose triptolide in combination with idarubicin induces apoptosis in AML leukemic stem-like KG1a cell line by modulation of the intrinsic and extrinsic factors. Cell Death Dis (2013) 0.90
Application of a trifunctional reactive linker for the construction of antibody-drug hybrid conjugates. Bioorg Med Chem Lett (2008) 0.90
The bone marrow stroma in hematological neoplasms--a guilty bystander. Nat Rev Clin Oncol (2011) 0.89
The bad and the good of mesenchymal stem cells in cancer: Boosters of tumor growth and vehicles for targeted delivery of anticancer agents. World J Stem Cells (2010) 0.88
xCELLigence system for real-time label-free monitoring of growth and viability of cell lines from hematological malignancies. Onco Targets Ther (2014) 0.88
Impact of CXCR4 inhibition on FLT3-ITD-positive human AML blasts. Exp Hematol (2009) 0.88
Role of integrin alpha4 in drug resistance of leukemia. Front Oncol (2014) 0.88
Acquisition of anoikis resistance in human osteosarcoma cells does not alter sensitivity to chemotherapeutic agents. BMC Cancer (2005) 0.88
Identification of hepatic niche harboring human acute lymphoblastic leukemic cells via the SDF-1/CXCR4 axis. PLoS One (2011) 0.88
Targeting self-renewal pathways in myeloid malignancies. Cell Commun Signal (2013) 0.87
SP/drug efflux functionality of hematopoietic progenitors is controlled by mesenchymal niche through VLA-4/CD44 axis. Leukemia (2013) 0.87
Acquisition of resistance toward HYD1 correlates with a reduction in cleaved α4 integrin expression and a compromised CAM-DR phenotype. Mol Cancer Ther (2011) 0.86
Mesenchymal stromal cells derived from acute myeloid leukemia bone marrow exhibit aberrant cytogenetics and cytokine elaboration. Blood Cancer J (2015) 0.85
Targeting the microenvironment in acute myeloid leukemia. Curr Hematol Malig Rep (2015) 0.84
Targeting myelogenous leukemia stem cells: role of the circulation. Front Oncol (2012) 0.84
Rationally engineered nanoparticles target multiple myeloma cells, overcome cell-adhesion-mediated drug resistance, and show enhanced efficacy in vivo. Blood Cancer J (2012) 0.84
Bone marrow stromal cells modulate mouse ENT1 activity and protect leukemia cells from cytarabine induced apoptosis. PLoS One (2012) 0.84
Establishment of a xenograft model of human myelodysplastic syndromes. Haematologica (2010) 0.84
Activation of the vascular niche supports leukemic progression and resistance to chemotherapy. Exp Hematol (2014) 0.83
Phase I clinical, pharmacokinetic, and pharmacodynamic study of the Akt-inhibitor triciribine phosphate monohydrate in patients with advanced hematologic malignancies. Leuk Res (2013) 0.83
New strategies in acute myelogenous leukemia: leukemogenesis and personalized medicine. Clin Cancer Res (2014) 0.83
Functional and structural insights into ASB2alpha, a novel regulator of integrin-dependent adhesion of hematopoietic cells. J Biol Chem (2011) 0.83
Novel postremission strategies in adults with acute myeloid leukemia. Curr Opin Hematol (2009) 0.83
Leukemia Mediated Endothelial Cell Activation Modulates Leukemia Cell Susceptibility to Chemotherapy through a Positive Feedback Loop Mechanism. PLoS One (2013) 0.83
Cancer stem cells: progress and challenges in lung cancer. Stem Cell Investig (2014) 0.83
Targeting BTK for the treatment of FLT3-ITD mutated acute myeloid leukemia. Sci Rep (2015) 0.83
The pathogenic relevance of the prognostic markers CD38 and CD49d in chronic lymphocytic leukemia. Ann Hematol (2013) 0.83
Real-time analysis of the inside-out regulation of lymphocyte function-associated antigen-1 revealed similarities to and differences from very late antigen-4. J Biol Chem (2011) 0.82
Reelin promotes the adhesion and drug resistance of multiple myeloma cells via integrin β1 signaling and STAT3. Oncotarget (2016) 0.82
Leukemic Stem Cells Evade Chemotherapy by Metabolic Adaptation to an Adipose Tissue Niche. Cell Stem Cell (2016) 0.81
High VLA-4 expression is associated with adverse outcome and distinct gene expression changes in childhood B-cell precursor acute lymphoblastic leukemia at first relapse. Haematologica (2011) 0.81
Integrin VLA-5 and FAK are Good Targets to Improve Treatment Response in the Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia. Front Oncol (2014) 0.81
The membrane-proximal KXGFFKR motif of α-integrin mediates chemoresistance. Mol Cell Biol (2013) 0.81
Halogenated benzimidazole carboxamides target integrin alpha4beta1 on T-cell and B-cell lymphomas. Cancer Res (2010) 0.80
Human bone marrow niche chemoprotection mediated by cytochrome P450 enzymes. Oncotarget (2015) 0.80
Targeting the leukemia-stroma interaction in acute myeloid leukemia: rationale and latest evidence. Ther Adv Hematol (2016) 0.80
The intracellular form of human MAGP1 elicits a complex and specific transcriptional response. Int J Biochem Cell Biol (2007) 0.80
Functional inhibition of mesenchymal stromal cells in acute myeloid leukemia. Leukemia (2015) 0.80
Breaking and entering into the CNS: clues from solid tumor and nonmalignant models with relevance to hematopoietic malignancies. Clin Exp Metastasis (2013) 0.80
Extracellular matrix stiffness causes systematic variations in proliferation and chemosensitivity in myeloid leukemias. Proc Natl Acad Sci U S A (2016) 0.79
Molecular deconstruction, detection, and computational prediction of microenvironment-modulated cellular responses to cancer therapeutics. Adv Drug Deliv Rev (2014) 0.79
The regulation of normal and leukemic hematopoietic stem cells by niches. Cancer Microenviron (2012) 0.79
Significance of expression of ITGA5 and its splice variants in acute myeloid leukemia: a report from the Children's Oncology Group. Am J Hematol (2013) 0.79
Can immunotherapy specifically target acute myeloid leukemic stem cells? Oncoimmunology (2013) 0.79
Low expression of Abelson interactor-1 is linked to acquired drug resistance in Bcr-Abl-induced leukemia. Leukemia (2014) 0.79
Apoptotic death of hematopoietic tumor cells through potentiated and sustained adhesion to fibronectin via VLA-4. J Biol Chem (2009) 0.78
Osteoblastic and vascular endothelial niches, their control on normal hematopoietic stem cells, and their consequences on the development of leukemia. Stem Cells Int (2011) 0.78
Structure and function of the solid tumor niche. Front Biosci (Schol Ed) (2012) 0.78
RUNX1/ETO blocks selectin-mediated adhesion via epigenetic silencing of PSGL-1. Oncogenesis (2015) 0.78
Effector and memory CD8+ T cell fate coupled by T-bet and eomesodermin. Nat Immunol (2005) 8.27
Oligosaccharides of Hyaluronan activate dendritic cells via toll-like receptor 4. J Exp Med (2002) 5.70
Essential role of MD-2 in LPS responsiveness and TLR4 distribution. Nat Immunol (2002) 5.41
Noncanonical inflammasome activation by intracellular LPS independent of TLR4. Science (2013) 5.06
Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone. Nat Biotechnol (2008) 4.29
Role of the Toll-like receptor 4/NF-kappaB pathway in saturated fatty acid-induced inflammatory changes in the interaction between adipocytes and macrophages. Arterioscler Thromb Vasc Biol (2006) 4.07
Anomalous type 17 response to viral infection by CD8+ T cells lacking T-bet and eomesodermin. Science (2008) 4.04
Crystal structures of human MD-2 and its complex with antiendotoxic lipid IVa. Science (2007) 4.01
Virulence factors of Yersinia pestis are overcome by a strong lipopolysaccharide response. Nat Immunol (2006) 3.89
Requirement for T-bet in the aberrant differentiation of unhelped memory CD8+ T cells. J Exp Med (2007) 3.67
The program of gene transcription for a single differentiating cell type during sporulation in Bacillus subtilis. PLoS Biol (2004) 3.33
The S100A8-serum amyloid A3-TLR4 paracrine cascade establishes a pre-metastatic phase. Nat Cell Biol (2008) 3.30
Mediators of innate immune recognition of bacteria concentrate in lipid rafts and facilitate lipopolysaccharide-induced cell activation. J Cell Sci (2002) 3.29
Human mesenchymal stem cells xenografted directly to rat liver are differentiated into human hepatocytes without fusion. Blood (2005) 2.60
Expression of Toll-like receptor 2 on CD16+ blood monocytes and synovial tissue macrophages in rheumatoid arthritis. Arthritis Rheum (2004) 2.52
The forespore line of gene expression in Bacillus subtilis. J Mol Biol (2006) 2.52
Transgenic silkworms produce recombinant human type III procollagen in cocoons. Nat Biotechnol (2002) 2.42
Lipopolysaccharide interaction with cell surface Toll-like receptor 4-MD-2: higher affinity than that with MD-2 or CD14. J Exp Med (2003) 2.39
Establishment of a monoclonal antibody against human Toll-like receptor 3 that blocks double-stranded RNA-mediated signaling. Biochem Biophys Res Commun (2002) 2.19
Toll-like receptor 4 expression is required to control chronic Mycobacterium tuberculosis infection in mice. J Immunol (2002) 2.17
Treatment of pancreatic fibrosis with siRNA against a collagen-specific chaperone in vitamin A-coupled liposomes. Gut (2012) 2.17
Coagulation factor X activates innate immunity to human species C adenovirus. Science (2012) 2.09
Toll-like receptor 4 mediates synergism between alcohol and HCV in hepatic oncogenesis involving stem cell marker Nanog. Proc Natl Acad Sci U S A (2009) 2.07
Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease. Sci Transl Med (2013) 2.03
Mesenchymal stem cells that produce neurotrophic factors reduce ischemic damage in the rat middle cerebral artery occlusion model. Mol Ther (2005) 1.91
Lipid A antagonist, lipid IVa, is distinct from lipid A in interaction with Toll-like receptor 4 (TLR4)-MD-2 and ligand-induced TLR4 oligomerization. Int Immunol (2004) 1.91
Peroxiredoxin family proteins are key initiators of post-ischemic inflammation in the brain. Nat Med (2012) 1.90
BDNF gene-modified mesenchymal stem cells promote functional recovery and reduce infarct size in the rat middle cerebral artery occlusion model. Mol Ther (2004) 1.87
Long-term phlebotomy with low-iron diet therapy lowers risk of development of hepatocellular carcinoma from chronic hepatitis C. J Gastroenterol (2007) 1.85
TLR accessory molecules. Curr Opin Immunol (2008) 1.84
A significant reduction in serum alanine aminotransferase levels after 3-month iron reduction therapy for chronic hepatitis C: a multicenter, prospective, randomized, controlled trial in Japan. J Gastroenterol (2004) 1.83
Cathepsins are required for Toll-like receptor 9 responses. Biochem Biophys Res Commun (2007) 1.81
Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma. Blood (2012) 1.81
High-density lipoprotein suppresses the type I interferon response, a family of potent antiviral immunoregulators, in macrophages challenged with lipopolysaccharide. Circulation (2010) 1.80
Saturated fatty acid and TLR signaling link β cell dysfunction and islet inflammation. Cell Metab (2012) 1.77
Roles for LPS-dependent interaction and relocation of TLR4 and TRAM in TRIF-signaling. Biochem Biophys Res Commun (2008) 1.76
Intravenous administration of auto serum-expanded autologous mesenchymal stem cells in stroke. Brain (2011) 1.73
BRCA1 transcriptionally regulates damaged DNA binding protein (DDB2) in the DNA repair response following UV-irradiation. Cancer Biol Ther (2002) 1.72
Regulatory roles for MD-2 and TLR4 in ligand-induced receptor clustering. J Immunol (2006) 1.69
Mesenchymal stem cells (MSC) as therapeutic cytoreagents for gene therapy. Cancer Sci (2005) 1.68
Colorectal cancer: genetics of development and metastasis. J Gastroenterol (2006) 1.63
Structural basis of species-specific endotoxin sensing by innate immune receptor TLR4/MD-2. Proc Natl Acad Sci U S A (2012) 1.63
A protein associated with Toll-like receptor (TLR) 4 (PRAT4A) is required for TLR-dependent immune responses. J Exp Med (2007) 1.62
Fas-mediated apoptosome formation is dependent on reactive oxygen species derived from mitochondrial permeability transition in Jurkat cells. J Immunol (2004) 1.61
Unc93B1 restricts systemic lethal inflammation by orchestrating Toll-like receptor 7 and 9 trafficking. Immunity (2011) 1.59
Body iron metabolism and pathophysiology of iron overload. Int J Hematol (2008) 1.59
Saccharomyces cerevisiae- and Candida albicans-derived mannan induced production of tumor necrosis factor alpha by human monocytes in a CD14- and Toll-like receptor 4-dependent manner. Microbiol Immunol (2002) 1.57
Mycobacterium tuberculosis H37Rv3377c encodes the diterpene cyclase for producing the halimane skeleton. Chem Commun (Camb) (2005) 1.56
Omentum-preserving gastrectomy for advanced gastric cancer: a propensity-matched retrospective cohort study. Gastric Cancer (2012) 1.54
Unc93B1 biases Toll-like receptor responses to nucleic acid in dendritic cells toward DNA- but against RNA-sensing. J Exp Med (2009) 1.53
A patient with TP53 germline mutation developed Bowen's disease and myelodysplastic syndrome with myelofibrosis after chemotherapy against ovarian cancer. Intern Med (2005) 1.51
Structural reorganization of the Toll-like receptor 8 dimer induced by agonistic ligands. Science (2013) 1.47
Regulatory loop between redox sensing of the NADH/NAD(+) ratio by Rex (YdiH) and oxidation of NADH by NADH dehydrogenase Ndh in Bacillus subtilis. J Bacteriol (2006) 1.46
Cell activation by Porphyromonas gingivalis lipid A molecule through Toll-like receptor 4- and myeloid differentiation factor 88-dependent signaling pathway. Int Immunol (2002) 1.46
Human herpesvirus-6 hepatitis associated with cyclosporine-A encephalitis after bone marrow transplantation for chronic myeloid leukemia. Intern Med (2006) 1.41
Two waves of memory B-cell generation in the primary immune response. Int Immunol (2005) 1.36
Requirement for MD-1 in cell surface expression of RP105/CD180 and B-cell responsiveness to lipopolysaccharide. Blood (2002) 1.35
Learning curve for laparoscopy-assisted distal gastrectomy with regional lymph node dissection for early gastric cancer. Surg Laparosc Endosc Percutan Tech (2008) 1.34
The radioprotective 105/MD-1 complex links TLR2 and TLR4/MD-2 in antibody response to microbial membranes. J Immunol (2005) 1.33
Analysis of the Bacillus subtilis spoIIIJ gene and its Paralogue gene, yqjG. J Bacteriol (2002) 1.32
Telomerized human multipotent mesenchymal cells can differentiate into hematopoietic and cobblestone area-supporting cells. Exp Hematol (2003) 1.29
Squalene-hopene cyclase: catalytic mechanism and substrate recognition. Chem Commun (Camb) (2002) 1.28
BRCA1 directs a selective p53-dependent transcriptional response towards growth arrest and DNA repair targets. Mol Cell Biol (2002) 1.28
Critical role for Ets, AP-1 and GATA-like transcription factors in regulating mouse Toll-like receptor 4 (Tlr4) gene expression. Biochem J (2005) 1.28